Johnson & JohnsonJNJ
JNJ
About: Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
Employees: 139,800
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
81% more call options, than puts
Call options by funds: $4.67B | Put options by funds: $2.57B
66% more first-time investments, than exits
New positions opened: 242 | Existing positions closed: 146
54% more funds holding in top 10
Funds holding in top 10: 144 [Q4 2024] → 222 (+78) [Q1 2025]
10% more capital invested
Capital invested by funds: $257B [Q4 2024] → $283B (+$26.5B) [Q1 2025]
1% more funds holding
Funds holding: 4,047 [Q4 2024] → 4,068 (+21) [Q1 2025]
0.94% less ownership
Funds ownership: 71.86% [Q4 2024] → 70.92% (-0.94%) [Q1 2025]
8% less repeat investments, than reductions
Existing positions increased: 1,672 | Existing positions reduced: 1,810
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$153
9%
downside
Avg. target
$175
4%
upside
High target
$190
13%
upside
7 analyst ratings
2 positive
29%
5 neutral
71%
0 negative
0%
Barclays Matt Miksic | 5%upside $176 | Equal-Weight Maintained | 17 Jul 2025 |
RBC Capital Shagun Singh | 10%upside $185 | Outperform Maintained | 17 Jul 2025 |
Guggenheim Vamil Divan | 1%downside $167 | Neutral Maintained | 17 Jul 2025 |
UBS Danielle Antalffy | 13%upside $190 | Buy Maintained | 17 Jul 2025 |
Morgan Stanley Terence Flynn | 5%upside $176 | Equal-Weight Maintained | 17 Jul 2025 |
Financial journalist opinion
Based on 118 articles about JNJ published over the past 30 days
Neutral
Business Wire
11 hours ago
Boston Jury Hits Johnson & Johnson with Record $42M Verdict in Asbestos Baby Powder Case
BOSTON--(BUSINESS WIRE)--A Boston jury has sided with Paul and Kathryn Lovell in a lawsuit against cosmetic behemoth Johnson & Johnson (NYSE:JNJ) that asserted Mr. Lovell's mesothelioma was directly caused by the company's iconic, asbestos-laced baby powder. The jury awarded $42,609,300, making it what lawyers believe to be the largest mesothelioma verdict in Massachusetts history. During the two-week trial, jurors heard compelling arguments from Dean Omar Branham Shirley attorneys Aaron Ch.
Positive
Investors Business Daily
16 hours ago
Dow Jones Health Care Giant J&J, Three Others In Or Near Buy Zones
Dow Jones health care giant Johnson & Johnson is approaching a new buy point, while AI stocks Argan and Constellation are near buy zones.
Neutral
PRNewsWire
23 hours ago
Johnson & Johnson Launches VIRTUGUIDE™ AI-Powered Patient-Matched Lapidus System in U.S. to Reduce Complexity in Bunion Surgery for Millions
Early VIRTUGUIDE™ surgeons report a 30-minute reduction in surgical time versus traditional treatment1 ,2 , *,** WEST CHESTER, Penn. , July 29, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) – Johnson & Johnson MedTech, a global leader in orthopaedic technologies and solutions, today announced the launch of the VIRTUGUIDE™ System.
Neutral
PRNewsWire
23 hours ago
Johnson & Johnson files with U.S. FDA to include new evidence in TREMFYA® (guselkumab) label as the only IL-23 inhibitor to demonstrate significant inhibition of joint structural damage in active psoriatic arthritis
Submission is supported by 24-week results from the Phase 3b APEX study in adults with active psoriatic arthritis treated with TREMFYA ® , the only dual-acting IL-23 inhibitor HORSHAM, Pa. , July 29, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval to include new evidence in the TREMFYA® (guselkumab) label for the inhibition of progression of structural damage in adults with active psoriatic arthritis (PsA).
Positive
The Motley Fool
1 day ago
2 Unstoppable Dow Dividend Stocks to Buy and Hold Forever
The Dow Jones Industrial Average tracks 30 of the country's top companies. These mature companies tend to be very profitable, enabling them to pay sustainable dividends.
Positive
The Motley Fool
1 day ago
Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Forever
Healthcare stocks aren't exactly known for offering large yields, with the average healthcare stock at just 1.8% or so. You can do better than that and get reliable dividend stocks while you are at it.
Neutral
24/7 Wall Street
1 day ago
5 Dogs of the Dow Are Crushing the S&P 500 and Nasdaq in 2025
The Dogs of the Dow is a well-known strategy first published in 1991 by Michael O'Higgins.
Neutral
24/7 Wall Street
1 day ago
4 High-Yield Blue-Chip Pharmaceutical Giants Offer Huge Total Return Potential
With some pharmaceutical stocks paying dividends as high as 7%, they look even more substantial if Treasury yields continue to drop.
Positive
24/7 Wall Street
2 days ago
3 Top Dividend Kings I'm Planning on Buying
Finding dividend stocks that are reliable and have the balance sheet stability and cash flow profile to continue to grow their distributions over the long-term is what many investors are after.
Positive
Seeking Alpha
2 days ago
22 Dividend Kings At Discounted Valuations
Dividend kings can offer reliable income growth and capital appreciation, making them attractive for long-term investors. During our screening today, we have 22 dividend kings trading at what could be considered attractive valuations based on P/E, dividend, and analyst estimates. We take a closer look at three of these names that make the list, but all could be considered candidates to take a deeper dive into as potential investment opportunities.
Charts implemented using Lightweight Charts™